John L. Nitiss
Molecular Pharmacology Department
St. Jude Children's Research Hospital
Memphis
Tennessee 38105
USA
Name/email consistency: high
- DNA topoisomerase II and its growing repertoire of biological functions. Nitiss, J.L. Nat. Rev. Cancer (2009)
- Targeting DNA topoisomerase II in cancer chemotherapy. Nitiss, J.L. Nat. Rev. Cancer (2009)
- Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis). Nitiss, J.L., Nitiss, K.C. IDrugs (2005)
- A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells. Walker, J.V., Nitiss, K.C., Jensen, L.H., Mayne, C., Hu, T., Jensen, P.B., Sehested, M., Hsieh, T., Nitiss, J.L. J. Biol. Chem. (2004)
- A copper connection to the uptake of platinum anticancer drugs. Nitiss, J.L. Proc. Natl. Acad. Sci. U.S.A. (2002)
- DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Nitiss, J.L. Curr. Opin. Investig. Drugs (2002)
- Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage. Nitiss, J.L., Nitiss, K.C., Rose, A., Waltman, J.L. J. Biol. Chem. (2001)
- Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Nitiss, J.L. Biochim. Biophys. Acta (1998)
